Evidence map›Paper›PMID 40444374›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025

Acute flaccid myelitis in Europe between 2016 and 2023: indicating the need for better registration.

Jelte Helfferich, Cristina Calvo, Ekkehardt Alpeter, Cristina Andrés, Andrés Antón, Melodie Aubart, Stefania Maria Bova, Maria Cabrerizo, Karin von Eije, Stollar Fabiola and 32 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Jelte HelfferichDepartment of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Cristina CalvoCentro de Investigación Biomédica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain.
Ekkehardt AlpeterFederal Department of Home Affairs FDHA, Federal Office of Public Health FOPH, Division of Communicable Disease, Bern, Switzerland.
Cristina AndrésCentro de Investigación Biomédica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain.
Andrés AntónCentro de Investigación Biomédica en red de Enfermedades Infecciosas CIBERINFEC, Instituto Carlos III, Madrid, Spain.
Melodie AubartPediatric Neurology Department, Necker-Enfants malades Hospital, AP-HP, Paris, France.
Stefania Maria BovaChild Neurology Unit, Buzzi Children hospital, Milan, Italy.
Maria CabrerizoPolio/Enterovirus National Lab, National Centre of Microbiology, Instituto de Salud Carlos III, Madrid, Spain. CIBERESP and RITIP (Idipaz).
Karin von EijeDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
Stollar FabiolaDivision of General Pediatrics, Department of Pediatrics, Gynecology & Obstetrics, University Hospitals of Geneva, Geneva, Switzerland.
Ana FelipePaediatric Neurology Research Group, Vall d'Hebron Institut de Recerca, Barcelona, Catalonia, Spain.
Ralitsa IordanovaDepartment of Pediatrics UMHAT "St. George" - Plovdiv, Plovdiv, Bulgaria.
Marianne Kragh ThomsenDepartment of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark.
Per Kristian KnudsenDepartment of Paediatric and Adolescent Medicine and Department of Paediatric Research, Oslo University Hospital, Oslo, Norway.
Freek van LoenenDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
Noemi LopezCentro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
Audrey MirandCHU Clermont-Ferrand, Centre National de référence des entéroviurs et parechovirus-laboratoire coordonnateur, Clermont-Ferrand, France.
Richard MolenkampDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
Sofie MidgleyThe Danish WHO National Reference Laboratory for Poliovirus, Section for Virus Genomics, Department of Virus & Microbiological Preparedness, Division of Infectious Disease Diagnostic Preparedness, Copenhagen, Denmark.
Raquel NevesNational Reference Laboratory for Vaccine-Preventable Diseases, Department of Infectious Diseases, National Institute of Health, Doutor Ricardo Jorge, Lisbon, Portugal.
Lubomira Nikolaeva GlombNational Reference Laboratory for Enteroviruses, National Center for Infectious and Parasitic Diseases, Sofia, Bulgaria.
Joakim ØverbøThe Norwegian Institute of Public Health (NIPH), Oslo, Norway.
Gülten ÖztürkDepartment of pediatric neurology, Marmara University, Istanbul, Türkiye.
Paula PalminhaNational Reference Laboratory for Vaccine-Preventable Diseases, Department of Infectious Diseases, National Institute of Health, Doutor Ricardo Jorge, Lisbon, Portugal.
Helle Cecilie Viekilde PfeifferDepartment of Pediatrics, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark.
Birgit ProchazkaAGES, Wien, Austria.
Carlos RibeiroNational Reference Laboratory for Vaccine-Preventable Diseases, Department of Infectious Diseases, National Institute of Health, Doutor Ricardo Jorge, Lisbon, Portugal.
Martine RodeschDepartment of pediatrics, Hôpital Erasme, Brussels, Belgium.
Isabelle SchuffeneckerDepartment of Virology, National Reference Centre for Enteroviruses and Parechoviruses, Associated Laboratory, Université Claude Bernard Lyon 1, CHU Lyon, Lyon, France.
Jay ShettyDepartment of Paediatric Neurosciences, Royal Hospital for Children and Young People, Edinburgh, United Kingdom.
Sandy SiegertDivision of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Silje Lae SolbergDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Artur SulikDepartment of Pediatric Infectious Diseases, Medical University of Bialystok, Bialystok, Poland.
Dilşad TürkdoğanDepartment of pediatric neurology, Marmara University, Istanbul, Türkiye.
Olcay ÜnverDepartment of pediatric neurology, Marmara University, Istanbul, Türkiye.
Jaco VerweijMicrovida Laboratory for Medical Microbiology and Immunology, ElisabethTweesteden Hospital, Tilburg, The Netherlands.
Jorgina VilaInfection and Immunity Research Group, Vall d'Hebron Institut de Recerca, Barcelona, Catalonia, Spain.
Tytti VuorinenDepartment of Clinical Microbiology, Turku University Hospital, Turku, Finland.
Ronny WickströmNeuropediatric Unit, Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Thea K FischerDepartment of Public Health, Section of Global Health, University of Copenhagen, Copenhagen, Denmark.
Heli HarvalaDepartment of Infection and Immunity, University College of London, London, United Kingdom.
Kimberley S M BenschopCentre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundAcute flaccid myelitis (AFM) is a rare polio-like condition affecting mainly children and characterised by severe, often persistent, weakness. It is one of several causes of acute flaccid paralysis (AFP), which manifests as acute onset of limb weakness and reduced muscle tone. Some non-polio enteroviruses (EV), such as EV-D68 may cause AFM. Little is known about AFM incidence in Europe.AimWe aimed to better understand AFM incidence, aetiology and current surveillance policies in Europe.MethodsIn 28 countries, members of the European non-polio enterovirus network (ENPEN) and a newly established AFM network of clinicians under ENPEN received a survey asking them how AFM surveillance was performed in their countries in 2016-2023 and the numbers of AFM cases including those diagnosed with EV-D68 infection during this period.ResultsSurveillance information was obtained for 16 countries. In eight countries, AFP surveillance initiated for poliomyelitis eradication was still ongoing, while non-polio AFM cases were only systematically reported in Norway. The survey revealed 130 AFM cases for 14 countries, with 48 (37%) EV-D68-laboratory-confirmed. Among the AFM cases, 70% (n = 91) occurred in 2016, 2018 and 2022, when EV-D68 circulation increased.ConclusionsThis report provides some indication of AFM case numbers in Europe since 2016. However, as 15 of 16 countries with AFM monitoring information lacked structural AFM surveillance, numbers should be interpreted with caution. Knowing AFM incidence matters to determine its impact and detect future outbreaks. Thus, the newly established clinical network will develop a European AFM repository.

Indexed as

Central Nervous System Viral DiseasesEnterovirus D, HumanEnterovirus InfectionsMyelitisNeuromuscular DiseasesPopulation SurveillanceRegistriesAdolescentChildChild, PreschoolDisease NotificationEuropeFemaleHumansIncidenceInfantAcute flaccid myelitisAcute flaccid paralysisChildrenEnterovirus A71Enterovirus D68Surveillance

Identifiers

PMID40444374
PMCPMC12124111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.